Browse views: by Year, by Function, by GLF, by Subfunction, by Conference, by Journal

Design of potent and selective covalent inhibitors of Bruton’s Tyrosine Kinase targeting an inactive conformation

Pulz, Robert and Angst, Daniela and Dawson King, Janet and Gessier, Francois and Gutmann, Sascha and Hersperger, Rene and Hinniger, Alexandra and Janser, Philipp and Koch, Guido and Revesz, Laszlo and Vulpetti, Anna and Waelchli, Rudolf and Cenni, Bruno and Zimmerlin, Alfred Gilbert (2019) Design of potent and selective covalent inhibitors of Bruton’s Tyrosine Kinase targeting an inactive conformation. ACS Medicinal Chemistry Letters, 10 (10). pp. 1467-1472. ISSN 1948-58751948-5875

Abstract

Bruton’s tyrosine kinase (BTK) is a member of the TEC kinase family and is selectively expressed in a subset of immune cells. It is a key regulator of antigen receptor signaling in B cells and of Fc receptor signaling in mast cells and macrophages. A BTK inhibitor will likely have a positive impact on autoimmune diseases which are caused by autoreactive B cells and immune-complex driven inflammation. We report the design, optimization, and characterization of potent and selective covalent BTK inhibitors. Starting from the selective reversible inhibitor 3 binding to an inactive conformation of BTK, we designed covalent irreversible compounds by attaching an electrophilic warhead to reach Cys481. The first prototype 4 covalently modified BTK and showed an excellent kinase selectivity including several Cys-containing kinases, validating the design concept. In addition, this compound blocked FcγR-mediated hypersensitivity in vivo. Optimization of whole blood potency and metabolic stability resulted in compounds such as 8, which maintained the excellent kinase selectivity and showed improved BTK occupancy in vivo.

Item Type: Article
Date Deposited: 26 Oct 2019 00:45
Last Modified: 26 Oct 2019 00:45
URI: https://oak.novartis.com/id/eprint/40217

Search

Email Alerts

Register with OAK to receive email alerts for saved searches.